FibroScan Limitations: Australian Clinic Guide
FibroScan has documented limitations in obese patients, workflow efficiency, and operator guidance. What the evidence shows and why guided TE addresses the root causes.
Read article →Blog
Data-led articles and buyer guides for Australian clinicians evaluating liver elastography.
8 of 8 articles
Portable Liver Elastography for Regional Australia
Regional and rural Australian practices face a liver disease access gap. Guided elastography systems are changing that — here's what regional clinics need to know.
Read article →Elastography ROI for Australian Private Clinics
How to model the return on investment for adding guided liver elastography to a private clinic or imaging centre in Australia. Scan economics, payback periods, and revenue projections.
Read article →MBS Rebate for Liver Elastography: 2025 Status Update
MSAC Application 1797 was rejected in early 2025 — no MBS rebate for liver elastography currently exists. What happened, what it means, and what comes next.
Read article →FIB-4 Indeterminate: What Comes Next in Practice?
Operational discussion of how clinics handle indeterminate FIB-4 results and when non-invasive staging pathways are considered.
Read article →GP Liver Screening: A Practical Primary-Care Pathway
How GP clinics can structure consistent liver risk workflows with clear triage, follow-up, and referral logic.
Read article →Liver Scan in Obese Patients: Australian Clinic Guide
Operational guide to non-invasive liver assessment in higher-BMI cohorts, including workflow and acquisition considerations.
Read article →FibroScan Alternatives Australia: Guided Elastography Buyer's Guide
What Australian buyers evaluate when comparing transient elastography systems: guidance, workflow, obese-patient performance, probes, and total cost of ownership.
Read article →